Multiple sclerosis (MS)
For the examination of the pathogenesis and treatment of MS, the primary MS model, experimental autoimmune encephalomyelitis (EAE), has been established in rhesus monkeys and in, at 8 variants, common marmosets. The marmoset EAE model in particular has been successfully used in unraveling how the interaction of genetic (MHC) and environmental (infections) may elicit pathogenic autoimmune reactions leading to MS-like disease. In the 15 years after its introduction at BPRC the model has been used for biomarker identification in blood and urine and for the development of magnetic resonance imaging (MRI) and well-validated via a series of new immunotherapies.
Preclinical models of multiple sclerosis in nonhuman primates.
't Hart BA, Jagessar SA, Kap YS, Brok HP.
Expert Rev Clin Immunol. 2007 Sep;3(5):749-61.
Experimental autoimmune encephalomyelitis in the common marmoset, a bridge between rodent EAE and multiple sclerosis for immunotherapy development.
Kap YS, Laman JD, 't Hart BA. J Neuroimmune Pharmacol. 2010 Jun;5(2):220-30.
Effects of early IL-17A neutralization on disease induction in a primate model of experimental autoimmune encephalomyelitis.
Kap YS, Jagessar SA, van Driel N, Blezer E, Bauer J, van Meurs M, Smith P, Laman JD, 't Hart BA.
J Neuroimmune Pharmacol. 2011 Sep;6(3):341-53.
Immune profile of an atypical EAE model in marmoset monkey immunized with recombinant human myelin oligodendrocyte glycoprotein in incomplete Freund's adjuvant.
Jagessar SA, Heijmans N, Blezer EL, Bauer J, Weissert R, 't Hart BA.
J Neuroinflammation. 2015 Sep 17;12(1):169.
The primate autoimmune encephalomyelitis model; a bridge between mouse and man.
't Hart BA, van Kooyk Y, Geurts JJ, Gran B.
Ann Clin Transl Neurol. 2015 May;2(5):581-93.